Agilent Posts Double-Digit Growth in Q1 Mass Spec Sales, Highlights Diagnostic Ambitions | GenomeWeb

Agilent this week posted fiscal first quarter 2012 revenues of $1.64 billion, an 8 percent increase over $1.52 billion a year ago, and slightly short of Wall Street estimates of $1.65 billion.

The company's Life Sciences revenues rose 14 percent to $461 million from $404 million in the first quarter of 2011. Pharma/biotech revenues grew 18 percent and academic/government revenues rose 7 percent.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.

Clinicians look to fold non-medical data into algorithms to predict patients' health, the Wall Street Journal reports.

Connecticut's biotech investment is leading to the building of labs to house new startups, the Associated Press reports.

Craig Venter's Health Nucleus aims to change preventive medicine, according to the Robb Report.